Holen Sie sich die Stockscreener-App
0.189
38.67%
0.054
Schlusskurs vom Vortag:
$0.135
Offen:
$0.1919
24-Stunden-Volumen:
272.90M
Relative Volume:
59.68
Marktkapitalisierung:
$1.33M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.70M
KGV:
-0.0432
EPS:
-4.38
Netto-Cashflow:
$-26.07M
1W Leistung:
-58.40%
1M Leistung:
-62.55%
6M Leistung:
-76.18%
1J Leistung:
-91.13%
1-Tages-Spanne:
$0.156
$0.206
1-Wochen-Bereich:
$0.121
$0.49
52-Wochen-Spanne:
$0.121
$3.4899
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Firmenname
Hepion Pharmaceuticals Inc
Sektor
Branche
Telefon
732-902-4000
Adresse
399 THORNALL STREET, EDISON
Vergleichen Sie HEPA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.1869 | 1.33M | 0 | -22.70M | -26.07M | -4.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.73 | 110.00B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 74.82B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
653.35 | 38.43B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
272.87 | 34.12B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.75 | 27.56B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-07-20 | Fortgesetzt | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Aktie (HEPA) Neueste Nachrichten
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales - Benzinga
Hepion Pharmaceuticals launches public offering for proceeds of up to $9M; shares tumble - MSN
Stock market today: Star Fashion Culture Holdings jumped by 680.92% while Hepion Pharmaceuticals saw increase of 147.54% in early trading - Business Upturn
Hepion Pharmaceuticals launches $9 million stock offering - Investing.com India
Hepion Pharmaceuticals announces $9M public offering - TipRanks
Hepion Pharmaceuticals Announces $9.0 Million Public Offering - The Manila Times
Hepion Pharmaceuticals Announces $9M Public Offering with Dual Warrant Structure - StockTitan
Hepion Pharmaceuticals faces potential Nasdaq delisting - Investing.com
HEPA stock touches 52-week low at $0.43 amid market challenges - Investing.com
HEPA stock touches 52-week low at $0.43 amid market challenges By Investing.com - Investing.com South Africa
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
HEPA stock touches 52-week low at $0.46 amid market challenges - Investing.com Canada
Comparing Novo Nordisk A/S (NYSE:NVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
HEPA stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals Terminates Merger with Pharma Two B - TipRanks
HEPA stock touches 52-week low at $0.49 amid market challenges - Investing.com
Hepion Pharmaceuticals cancels merger and stockholder meeting By Investing.com - Investing.com Canada
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - The Manila Times
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Pharma Two B Announces Poster Presentation on P2B001 at the - GlobeNewswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Hepion urges shareholder support for Pharma Two B merger - Investing.com India
Hepion urges shareholder support for Pharma Two B merger By Investing.com - Investing.com Canada
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - The Manila Times
Hepion Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals faces Nasdaq delisting risk - Investing.com India
HEPA (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Long-Term Debt & Capital Leas - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Hepio - GuruFocus.com
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
Finanzdaten der Hepion Pharmaceuticals Inc-Aktie (HEPA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
5.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):